1. United Kingdom Stocks

  2. •

    Miscellaneous

  3. •

    Miscellaneous
Sareum Holdings plc

Sareum Holdings plc

LLSE:SAR
27.50
GBX
0.00
(0.00%)
2.07BMarket Cap
Oct 26Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.02
-0.02
-0.03
-0.02
0.01
-0.03
-0.03
-0.02
-0.02
-0.03
-0.05
-0.04
-0.04
- -
Free Cash Flow per Basic Share
-0.02
-0.02
-0.02
-0.01
0.02
-0.03
-0.02
-0.01
-0.02
-0.03
-0.05
-0.05
-0.02
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.01
0.05
0.04
0.04
0.04
0.03
0.02
0.03
0.04
0.06
0.02
0.02
0.02
0.01
Tangible Book Value per Share
0.01
0.05
0.04
0.04
0.04
0.03
0.02
0.03
0.04
0.06
0.02
0.02
0.02
0.01
Basic Weighted Avg Shares
30
34
39
50
53
54
57
62
65
68
68
81
124
136
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
-2,319.61
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-1
-1
-1
-1
- -
-1
-1
-1
-1
-2
-3
-3
-4
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
-2,088.62
- -
- -
- -
- -
- -
- -
Working Capital
- -
1
2
1
2
2
1
2
3
4
1
2
2
1
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
2
2
2
2
2
1
2
3
4
1
2
2
1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-117.27
-70.58
-70.02
-56.25
19.02
-73.88
-106.53
-68.05
-65.24
-60.96
-116.41
-209.37
-202.14
- -

Capital Structure

GBP

•

in mil. unless spec.
Dec'25
Jun'25
Dec'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
125
134
138
Market Capitalization
31
22
21

Working Capital

GBP

•

in mil. unless spec.
Dec'25
Jun'25
Dec'26
Total Current Assets
5
4
3
Cash, Cash Equivalents & STI
4
4
2
Accounts Receivable, Net
1
- -
1
Inventories
- -
- -
- -
Total Current Liabilities
- -
2
2
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

GBP

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.5%
25.52%
7.71%
Free Cash Flow
-39.88%
33.28%
-34.91%
Net Income, GAAP
-47.43%
36.16%
29.77%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.04
2025
- -
- -
-0.04
2026
- -
- -
- -

Semi-annual Dividends Per Share

GBP

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Stephen Barry Parker DPhil
Full Time Employees
5
Sector
Miscellaneous
Industry
Miscellaneous
Address
Langford Arch Cambridge CA United Kingdom CB22 3FX
IPO Date
Oct 11, 2004
Website
sareum.com
Similar Companies
X5 Corporate Center (MOEX:X5)
CID HoldCo, Inc. (NASDAQ:DAIC)
Borusan Yatirim ve Pazarlama AS (BIST:BRYAT)
PASIFIK HOLDING A.S (BIST:PAHOL)
PT Indokripto Koin Semesta Tbk (IDX:COIN)
PT Raharja Energi Cepu Tbk (IDX:RATU)
Business
Sareum Holdings plc (SAR.L) is a United Kingdom-based clinical-stage biotechnology company focused on the discovery and development of next-generation small-molecule kinase inhibitors for autoimmune diseases and cancer. Founded in 2004 and headquartered in Cambridge, the company leverages its proprietary Sareum Kinase Inhibitor Library (SKIL) technology to advance drug candidates to preclinical or early clinical stages for licensing to pharmaceutical and biotechnology partners. Its core pipeline includes SDC-1801, a potent and selective TYK2/JAK1 inhibitor in development for autoimmune conditions such as psoriasis, rheumatoid arthritis, lupus, and inflammatory bowel disease following completion of a Phase 1 clinical trial demonstrating favorable safety and pharmacokinetics; SDC-1802, a TYK2/JAK1 inhibitor targeted at cancer and cancer immunotherapy applications; and SRA737, a clinical-stage oral Checkpoint kinase 1 (Chk1) inhibitor with a 63.5% net economic interest held by Sareum for potential monotherapy or combinations including low-dose gemcitabine, BET/PARP/Wee1 inhibitors, or immunotherapy in solid tumors such as ovarian, prostate, lung, and colorectal cancers. Recent developments include the acquisition of the SRA737 license from CRT Pioneer Fund in March 2025 after its reversion from a prior U.S. licensee, enhancing Sareum's control and revenue share; initiation of toxicology studies for SDC-1801 in May 2025 to support Phase 2 readiness, with an update in October 2025 noting a pause due to control-group findings; a strategic collaboration with AI-driven drug discovery firm Receptor.AI announced in August 2025 to accelerate development of blood-brain-barrier permeable TYK2/JAK1 inhibitors using AI for compound optimization and virtual screening; multiple equity fundraises such as institutional placements in March 2025 and subscriptions in 2024 totaling over £3 million to extend cash runway; and broker appointments including a joint corporate broker in October 2025 and sole broker changes earlier in the year. Sareum operates primarily from the UK with global research partnerships, including historical collaborations with the Institute of Cancer Research and Cancer Research UK, and targets licensing opportunities in major pharmaceutical markets.